Otology

Comparison of various treatment modalities for acute tinnitus†‡§

  1. Hyun Joon Shim MD*,
  2. Seong Jun Song MD,
  3. A Young Choi MD,
  4. Rae Hyung Lee MD,
  5. Sang Won Yoon MD

Article first published online: 22 NOV 2011

DOI: 10.1002/lary.22350

Issue

The Laryngoscope

The Laryngoscope

Volume 121, Issue 12, pages 2619–2625, December 2011

Additional Information

How to Cite

Shim, H. J., Jun Song, S., Choi, A. Y., Hyung Lee, R. and Won Yoon, S. (2011), Comparison of various treatment modalities for acute tinnitus. The Laryngoscope, 121: 2619–2625. doi: 10.1002/lary.22350

Author Information

  1. Department of Otolaryngology Head and Neck Surgery, Eulji Hospital, Eulji University School of Medicine, Seoul, Korea

*Department of Otolaryngology, Eulji University School of Medicine, Hagye 1 Dong 280-1, Nowongu, Seoul, Korea

  • †

    Financial support for the study was provided by Jeil Pharmaceutical Co., Ltd, Korea.

  • ‡

    The authors have no other funding, financial relationships, or conflicts of interest to disclose.

  • §

    Editor's Note: This Manuscript was accepted for publication June 8, 2011.

Publication History

  1. Issue published online: 21 NOV 2011
  2. Article first published online: 22 NOV 2011
  3. Manuscript Accepted: 8 JUN 2011
  4. Manuscript Revised: 4 JUN 2011
  5. Manuscript Received: 1 APR 2011

Funded by

  • Jeil Pharmaceutical Co., Ltd, Korea

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (286K)

Keywords:

  • Tinnitus;
  • alprazolam;
  • dexamethasone;
  • injection;
  • prostaglandin E1;
  • Level of Evidence: 1b

Abstract

Objectives/Hypothesis:

Because in most cases the development of tinnitus is triggered by cochlear damage, there exists the opportunity to eliminate tinnitus while the cochlear lesion is still reversible. Therefore, we evaluated the therapeutic effects of various treatment modalities on acute subjective idiopathic tinnitus (SIT) and investigated prognostic factors affecting the treatment outcome.

Study Design:

Prospective, controlled, double-blind trial.

Methods:

A total 107 patients who underwent treatment for unilateral SIT that had developed within the previous 3 months completed the study. The patients were randomly assigned into three groups according to the treatment modality: group I (n = 32), alprazolam orally for 3 months; group II (n = 35), as for group I plus four intratympanic dexamethasone (ITD) injections; and group III (n = 40), as for group II plus four intravenous injections of lipo-prostaglandin E1.

Results:

The improvement rate of group II (75.8%) was significantly higher than that of group I (40.3%; P < .05), and there was no significant difference in the improvement rate of group III (50.0%) compared with groups I and II (P > .05). The cure rates of group II (25.8%) and group III (20.0%) were significantly higher than that of group I (9.8%; P < .05). There was a significant correlation between the cure rate and duration of symptoms.

Conclusions:

The results of the present study indicate that ITD injection plus alprazolam medication is the best treatment choice for acute SIT within 3 months of development. Laryngoscope, 121:2619–2625, 2011

View Full Article (HTML) Get PDF (286K)